Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
503 Citations•2021•
William J. Sandborn, Brian G. Feagan, Geert D’Haens
Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis and key secondary end points were significantly improved with ozanimod as compared with placebo in both periods.
Abstract
Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Funded by Bristol Myers Squibb; True North ClinicalTrials.gov number, NCT02435992.).